摘要
目的:探讨阿帕替尼辅助三线化疗治疗晚期胃癌的应用价值。方法:选取2019年1月至2020年1月郑州大学附属肿瘤医院收治的62例晚期胃癌患者,根据其治疗方法不同将其分为对照组30例和观察组32例,其中对照组使用三线化疗,观察组在对照组基础上增加阿帕替尼辅助治疗。比较两组患者的疾病缓解率、血清肿瘤标志物水平;采用Barthel指数评估两组患者治疗前后生存质量并比较;比较两组患者的不良反应发生率。结果:治疗后,观察组的疾病缓解率高于对照组,差异具有统计学意义(P<0.05);观察组患者的癌胚抗原(CEA)、糖类抗原(CA)199、CA125水平均低于对照组,差异具有统计学意义(P<0.05);观察组患者的生存质量评分明显高于对照组,差异具有统计学意义(P<0.05)。治疗期间,两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿帕替尼辅助三线化疗治疗晚期胃癌可以降低肿瘤标志物水平,提高患者生存质量,且不良反应发生率较低。
Objective To investigate the value of apatinib assisted third-line chemotherapy in the treatment of advanced gastric cancer.Methods A total of 62 patients with advanced gastric cancer admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2019 to January 2020 were selected,according to their different treatment methods,they were divided into a control group with 30 cases,and an observation group with 32 cases.The control group was treated with third-line chemotherapy,and the observation group was additionally treated with apatinib adjuvant therapy.The disease remission rate and serum tumor markers were compared between the two groups.Barthel index was used to evaluate the quality of life of patients in the two groups before and after treatment.The incidence of adverse reactions was compared between the two groups.Results After treatment,the remission rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA)199 and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The scores of quality of life in the observation group was significantly higher than that of the control group,with statistical significance(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Apatinib assisted third-line chemotherapy is effective in the treatment of advanced gastric cancer,which can lower the levels of tumor markers,and improve the patients’quality of life,with a low incidence of adverse reactions.
作者
潘佳
别良玉
张瑜
林瑞
PAN Jia;BIE Liang-yu;ZHANG Yu;LIN Rui(The Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Zhengzhou 450000)
出处
《深圳中西医结合杂志》
2022年第8期5-8,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词
晚期胃癌
阿帕替尼
三线化疗
肿瘤标志物
Advanced gastric cancer
Apatinib
Third-line chemotherapy
Tumor marker
